Ogeda SRL
The score of Ogeda shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -19 % Total assets -19 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Ogeda's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Jun 2026
- Year ended 31 Dec 2024filed on 16 Jun 2025
- Year ended 31 Dec 2023filed on 10 Jun 2024
- Year ended 31 Dec 2022filed on 15 Jun 2023
- Year ended 31 Dec 2021filed on 24 Jun 2022
Ogeda's financial analysis
- Solvency99.8%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Ogeda
Ogeda's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0453.325.639
- VAT number
- BE0453325639
- Peppol
- Registered · 0208:0453325639 · as of 08 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Aug 1994
- Registered office
- 1800 Vilvoorde
- Latest accounts
- 2025 · filed on 02 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Ogeda (SRL) has been based in Vilvoorde since 1994, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of €5.16m and equity of €53.3m; its revenue is not published. Its solvency stands at 99.8%, above the median of its sector (60.4%).
Companies similar to Ogeda
Companies in the same business, of comparable size and area, outside its group.
- Baxter R and D Europe Research and experimental development on natural sciences and engineering Lessines · balance sheet €52.7m
- Fujirebio Europe Manufacture of other chemical products n.e.c. Ghent · balance sheet €81.8m
- Kaneka Eurogentec Manufacture of pharmaceutical preparations Seraing · balance sheet €115.4m
- Confo Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €37.8m
- Cellistic Manufacture of pharmaceutical preparations Mont-Saint-Guibert · balance sheet €41.6m
- Devgen Research and experimental development on natural sciences and engineering Ghent · balance sheet €130.9m
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
- CellCarta Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €22.4m
Frequently asked questions about Ogeda
What is the revenue of Ogeda?
Ogeda files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Ogeda?
In Belgium, the VAT number is the company number prefixed with BE: BE0453325639 for Ogeda, if the company is VAT-registered. Its company number (CBE) is 0453.325.639.
Where is the registered office of Ogeda?
According to the CBE register, the registered office of Ogeda is in 1800 Vilvoorde.
What is the equity of Ogeda?
At the close of the 2025 financial year, the equity of Ogeda amounts to 53,342,831 €, a solvency of 99.8% of total assets.
Who manages Ogeda?
The register lists 4 active mandates at Ogeda. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Ogeda
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →